Selected article for: "IFN response and type iii type"

Author: Lasfar, Ahmed; Abushahba, Walid; Balan, Murugabaskar; Cohen-Solal, Karine A.
Title: Interferon Lambda: A New Sword in Cancer Immunotherapy
  • Cord-id: d3p9nbgq
  • Document date: 2011_12_6
  • ID: d3p9nbgq
    Snippet: The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser e
    Document: The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we and other groups have shown in several animal models a potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy.

    Search related documents:
    Co phrase search for related documents
    • absence presence and activity pattern: 1
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • absence presence and adaptive immunity: 1, 2, 3, 4
    • absence presence and adaptive innate: 1, 2
    • absence presence and adaptive innate immune response: 1
    • absence presence and liver cancer: 1
    • absence presence and liver function: 1, 2
    • absence presence and liver transplantation: 1
    • absence presence and low response: 1, 2
    • absence presence and lung kidney: 1, 2, 3, 4
    • absence presence and lung kidney heart: 1
    • absence presence and lung metastasis: 1
    • absence presence and lymphoid tissue: 1, 2, 3, 4
    • active protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • active protein and adaptive immunity: 1
    • active protein and adaptive innate: 1
    • active protein and liver cancer: 1, 2
    • active protein and lymphoid tissue: 1, 2
    • activity pattern and acute respiratory syndrome: 1, 2